REGENTIS BIOMATERIALS LTD. RGNT

Healthcare SIC 3842 - Orthopedic, Prosthetic & Surgical Appliances & Supplies NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical Appliance and Supplies Manufacturing derived NYSE

Last close —
Market cap —
52-week range — - —

No price or market cap here: this company files no 10-K, so the only share count SEC publishes for it counts its ordinary shares in its home market, while its US listing is a depositary receipt standing for some number of them. That number is in no filing, so a price multiplied by that count is not this company's value and is not shown. The financial statements below are as filed.

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-24.16

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022
SG&A $6.6M$712.0K$1.1M—
Operating income -$7.0M$932.0K-$1.9M—
Pre-tax income $13.6M-$4.8M$4.1M—
Net income -$13.6M$4.8M-$4.1M—
EPS, basic -24.161.72-24.09—
EPS, diluted -24.161.72-24.09—
Shares, diluted (wtd. avg.) 566,7442.8M173,508—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022
Cash and equivalents $7.4M———
Total assets $7.6M$482.0K——
Short-term debt $1.2M$573.0K$325.0K—
Total current liabilities $2.9M$6.5M——
Total liabilities $2.9M$6.5M——
Retained earnings -$55.8M-$42.1M——
Total equity $4.7M-$41.1M-$45.9M-$42.1M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022
Operating cash flow -$1.4M-$641.0K-$1.2M—
Stock-based compensation $7.0M———
Financing cash flow $8.5M$525.0K$325.0K—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-021722.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -15M -10M -5M 0 5M Net income, FY2023: -4.1M Net income, FY2024: 4.8M Net income, FY2025: -13.6M FY2022 FY2023 FY2024 FY2025
Fiscal year FY2022FY2023FY2024FY2025
Revenue — — — —
Gross profit — — — —
Net income — -$4.1M $4.8M -$13.6M

Others in SIC 3842

TickerCompanyMarket capP/ERevenue growth
ISRG INTUITIVE SURGICAL INC $159.78B 57.5x 20.5%
EW Edwards Lifesciences Corp $51.34B 48.7x 11.5%
STE STERIS plc $22.63B 29.3x 8.7%
ZBH ZIMMER BIOMET HOLDINGS, INC. $18.80B 27.8x 7.2%
ALGN ALIGN TECHNOLOGY INC $10.98B 27.3x 0.9%
MSA MSA Safety Inc $7.03B 25.7x 3.7%
ESTA ESTABLISHMENT LABS HOLDINGS INC. $1.90B — 27.1%
CDRE Cadre Holdings, Inc. $1.28B 29.4x 7.5%